NAUT Stock Price, Nautilus Biotechnology, . Quote, Chart

Market Summary

USD2.40+0.04

Delayedas of 26 Apr 2024, 11:04 am

1.69%

NAUT Stock Price

View Fullscreen

NAUT RSI Chart

NAUT Valuation

Market Cap

295.2M

Price/Earnings (Trailing)

-4.64

Price/Free Cashflow

-5.45

NAUT Price/Earnings (Trailing)

NAUT Profitability

Return on Equity

-24%

Return on Assets

-20.84%

Free Cashflow Yield

-18.34%

NAUT Fundamentals

NAUT Earnings

Earnings (TTM)

-63.7M

Earnings Growth (Yr)

-26.96%

Earnings Growth (Qtr)

-7.22%

Breaking Down NAUT Revenue

52 Week Range

2.164.65

(Low)(High)

Last 30 days

-10.3%

Last 90 days

-21.7%

Trailing 12 Months

-4.1%

How does NAUT drawdown profile look like?

NAUT Financial Health

Current Ratio

19.39

NAUT Investor Care

Shares Dilution (1Y)

0.18%

Diluted EPS (TTM)

-0.52

Tracking the Latest Insider Buys and Sells of Nautilus Biotechnology, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	patel sujal m	bought	34,215	2.8409	12,044	ceo, president, and secretary
Mar 08, 2024	patel sujal m	bought	7,262	2.9885	2,430	ceo, president, and secretary
Mar 07, 2024	patel sujal m	bought	54,424	2.8866	18,854	ceo, president, and secretary
Mar 06, 2024	patel sujal m	bought	25,033	2.7014	9,267	ceo, president, and secretary
Mar 05, 2024	patel sujal m	bought	19,596	2.6464	7,405	ceo, president, and secretary
Sep 27, 2022	sankar subramanian	bought	10,149	2.0298	5,000	senior vp, product development
Sep 26, 2022	sankar subramanian	bought	20,250	2.025	10,000	senior vp, product development
Sep 23, 2022	weld gwen e	bought	60,765	2.0255	30,000	chief people officer
Sep 16, 2022	sankar subramanian	bought	75,446	2.1556	35,000	senior vp, product development
Sep 15, 2022	sankar subramanian	bought	87,752	2.1938	40,000	senior vp, product development

Which funds bought or sold NAUT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-62.74	-8,000	5,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-4,767	83,849	-%
Apr 17, 2024	Clarius Group, LLC	added	3.7	35,092	1,822,420	0.13%
Apr 16, 2024	Vanguard Capital Wealth Advisors	reduced	-8.75	-12,290	107,310	0.07%
Apr 15, 2024	HILLMAN CO	unchanged	-	-10,000	588,000	0.27%
Apr 05, 2024	GAMMA Investing LLC	unchanged	-	17.00	309	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-97.98	-1,687	33.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.77	-412,768	8,461,100	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	66.13	145,818	400,786	-%

Are Funds Buying or Selling NAUT?

Are funds buying NAUT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NAUT

No. of Funds

Unveiling Nautilus Biotechnology, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 17, 2023	perceptive advisors llc	10.1%	12,594,211	SC 13D/A
Mar 01, 2023	nautilus biotechnology, inc.	15.0%	18,947,732	SC 13D/A
Feb 13, 2023	cercano management llc	5.8%	7,172,985	SC 13G
Feb 14, 2022	ra capital management, l.p.	2.0%	2,436,430	SC 13G/A
Feb 10, 2022	vcvc v llc	2.9%	3,586,493	SC 13G

Recent SEC filings of Nautilus Biotechnology, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 11, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 06, 2024	EFFECT	EFFECT
Mar 06, 2024	424B5	Prospectus Filed
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Nautilus Biotechnology, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Nautilus Biotechnology, Inc. News

Latest updates

Nautilus Biotechnology, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-4.0%	306	318	331	346	350	359	372	385	398	385	393	76.00	85.00	151	85.00	19.00
Current Assets	-5.3%	177	187	167	170	187	261	303	327	349	352	375	69.00	78.00	1.00	-	17.00
Cash Equivalents	-73.8%	19.00	74.00	72.00	89.00	115	190	211	189	186	191	289	52.00	37.00	13.00	33.00	1.00
Net PPE	-0.4%	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	1.00	-	-	1.00
Liabilities	-2.1%	40.00	41.00	41.00	42.00	35.00	34.00	34.00	35.00	35.00	8.00	3.00	5.00	6.00	5.00	-	0.00
Current Liabilities	2.6%	9.00	9.00	8.00	8.00	7.00	6.00	6.00	6.00	6.00	4.00	3.00	5.00	3.00	0.00	0.00	0.00
Shareholder's Equity	-4.3%	265	277	290	304	315	325	338	350	364	378	390	5.00	5.00	5.00	0.00	-
Retained Earnings	-9.2%	-202	-185	-169	-153	-138	-125	-111	-96.40	-80.64	-63.95	-49.45	-38.73	-30.32	-0.17	-0.01	-14.71
Additional Paid-In Capital	0.7%	468	465	461	458	455	452	449	447	444	442	439	2.00	1.00	5.00	0.00	0.00
Accumulated Depreciation	10.9%	5.00	4.00	4.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00	-	-	1.00
Shares Outstanding	0.1%	125	125	125	125	125	125	124	124	124	71.00	44.00	-	-	-	-	-
Float	-	-	-	219	-	-	-	152	-	-	-	571	-	-	-	168	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																	(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-18.4%	-13.90	-11.74	-13.55	-12.52	-10.38	-9.56	-13.53	-12.33	-10.52	-14.18	-8.29	-6.25	-4.73	-3.37	-	-2.62	-
Share Based Compensation	-1.1%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	3.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00	-
Cashflow From Investing	-414.0%	-41.06	13.00	-2.25	-13.49	-64.06	-11.94	35.00	15.00	6.00	-83.98	-84.57	24.00	29.00	-16.29	-45.57	8.00	-
Cashflow From Financing	1481.3%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	329	-2.07	-	0.00	76.00	-	-

NAUT Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 47,251	$ 37,672
General and administrative	28,901	25,946
Total operating expenses	76,152	63,618
Other income (expense):
Interest income	12,550	5,816
Other expense	(73)	(122)
Total other income	12,477	5,694
Net loss	$ (63,675)	$ (57,924)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.51)	$ (0.46)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.51)	$ (0.46)
Weighted average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	124,919,144	124,589,555
Weighted average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	124,919,144	124,589,555

NAUT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 19,397	$ 114,523
Short-term investments	154,021	69,948
Prepaid expenses and other current assets	3,419	2,738
Total current assets	176,837	187,209
Property and equipment, net	4,267	3,700
Operating lease right-of-use assets	32,634	28,866
Long-term investments	90,647	129,169
Other long-term assets	1,180	1,108
Total assets	305,565	350,052
Current liabilities:
Accounts payable	1,639	1,272
Accrued expenses and other liabilities	3,945	3,528
Current portion of operating lease liability	3,538	1,991
Total current liabilities	9,122	6,791
Operating lease liability, net of current portion	31,090	28,337
Total liabilities	40,212	35,128
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 200,000,000 authorized as of December 31, 2023 and December 31, 2022, respectively; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	0	0
Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 125,068,601 and 124,865,485 shares issued and outstanding as of December 31, 2023 and 2022, respectively	13	12
Additional paid-in capital	467,834	455,330
Accumulated other comprehensive loss	(255)	(1,854)
Accumulated deficit	(202,239)	(138,564)
Total stockholders’ equity	265,353	314,924
Total liabilities and stockholders’ equity	$ 305,565	$ 350,052

About Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was incorporated in 2016 and is headquartered in Seattle, Washington.

CEO	Mr. Sujal M. Patel
WEBSITE	nautilus.bio
INDUSTRY	Biotechnology
EMPLOYEES	153

Nautilus Biotechnology, Inc. Frequently Asked Questions

What is the ticker symbol for Nautilus Biotechnology, Inc.? What does NAUT stand for in stocks?

NAUT is the stock ticker symbol of Nautilus Biotechnology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nautilus Biotechnology, Inc. (NAUT)?

As of Thu Apr 25 2024, market cap of Nautilus Biotechnology, Inc. is 295.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NAUT stock?

You can check NAUT's fair value in chart for subscribers.

What is the fair value of NAUT stock?

You can check NAUT's fair value in chart for subscribers. The fair value of Nautilus Biotechnology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nautilus Biotechnology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NAUT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nautilus Biotechnology, Inc. a good stock to buy?

The fair value guage provides a quick view whether NAUT is over valued or under valued. Whether Nautilus Biotechnology, Inc. is cheap or expensive depends on the assumptions which impact Nautilus Biotechnology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NAUT.